Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilmsRocco Mazzolini, María Lluch‐Senar, Irene Rodríguez-Arce et al.|Nature Biotechnology|2023Cited by 85
Meropenem–nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection modelTomefa E. Asempa, David P. Nicolau, Ana Motos et al.|International Journal of Antimicrobial Agents|2019Cited by 37
Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing <i>Enterobacteriaceae</i> in the Neutropenic Murine Lung Infection ModelTomefa E. Asempa, David P. Nicolau, Ana Motos et al.|Antimicrobial Agents and Chemotherapy|2019Cited by 27
Epidemiology, ventilation management and outcomes of COVID–19 ARDS patients versus patients with ARDS due to pneumonia in the Pre–COVID eraFleur–Stefanie L. I. M. van der Ven, Siebe G. Blok, Luciano C. P. Azevedo et al.|Respiratory Research|2024Cited by 15
1368. Assessment of the In Vivo Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against β-Lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection ModelTomefa E. Asempa, David P. Nicolau, Ana Motos et al.|Open Forum Infectious Diseases|2018Cited by 3